Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
United States
Mayo Clinic Scottsdale, Scottsdale, Arizona Sarah Cannon Research Institute Denver, Denver, Colorado Mayo Clinic Jacksonville, Jacksonville, Florida University of Indiana, Indianapolis, Indiana Dana-Farber Cancer Institute, Boston, Massachusetts Mayo Clinic Cancer Center, Rochester, Minnesota Nebraska Cancer Specialists, Omaha, Nebraska NYU Langone Health, New York, New York Memorial Sloan Kettering Cancer Center, New York, New York University of Texas MD Anderson Cancer Center, Houston, Texas NEXT Dallas, Irving, Texas NEXT Oncology, Fairfax, Virginia Last updated December 2025